MTAP缺陷型转移性尿路上皮癌的临床与基因组综合特征分析
研究在MD Anderson癌症中心193例和IMvigor210试验298例转移性尿路上皮癌患者中,分析MTAP缺陷(MTAPdef)的临床与基因组特征。MDACC队列中MTAPdef患者内脏转移更常见(75% vs 55.2%,p=0.02),总生存更差(中位12.3 vs 20.2个月,p=0.007,校正HR 1.93,95%CI 1.35-2.98);IMvigor210中MTAPlo患者内脏转移发生率更高(86.2% vs 72.5%,p=0.021),预后更差(中位OS 8.0 vs 11.3个月,p=0.042)。
要点
- MDACC队列中MTAPdef患者内脏转移比例显著高于MTAPprof(75% vs 55.2%,p=0.02)。
- MTAPdef与更差预后相关:MDACC中位OS 12.3 vs 20.2个月(p=0.007,校正HR 1.93,95%CI 1.35-2.98)。
- IMvigor210中MTAPlo患者内脏转移率86.2% vs 72.5%(p=0.021),中位OS 8.0 vs 11.3个月(p=0.042)。
核心结论
- MTAPdef转移性尿路上皮癌具有独特生物学行为,与早期内脏转移和更差预后相关,可能成为潜在治疗靶点。
研究设计与样本
- 在MD Anderson癌症中心193例转移性尿路上皮癌患者和IMvigor210二期试验298例患者中分析MTAPdef的临床与基因组特征。
- IMvigor210试验研究阿替利珠单抗用于顺铂不耐受和铂类难治性疾病。
主要发现
- MDACC队列中MTAPdef(n=48)较MTAPprof(n=145)内脏转移更常见(75% vs 55.2%,p=0.02)。
- MDACC队列MTAPdef中位总生存12.3个月 vs MTAPprof 20.2个月(p=0.007),校正HR 1.93(95%CI 1.35-2.98)。
- IMvigor210中MTAPlo(n=29)较MTAPhi(n=269)内脏转移发生率更高(86.2% vs 72.5%,p=0.021),中位OS 8.0 vs 11.3个月(p=0.042)。
- MTAPdef肿瘤中增生相关基因突变更常见(FGFR3:31% vs 8%;PI3KCA:31% vs 19%),异型增生相关基因改变较少(TP53:41% vs 67%;RB1:0% vs 16%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Deficiency of MTAP (MTAPdef) mainly occurs because of homozygous loss of chromosome 9p21, which is the most common copy-number loss in metastatic urothelial cancer (mUC). We characterized the clinical and genomic features of MTAPdef mUC in 193 patients treated at MD Anderson Cancer Center (MDACC) and 298 patients from the phase 2 IMvigor210 trial, which investigated atezolizumab in cisplatin-ineligible and platinum-refractory disease. In the MDACC cohort, visceral metastases were significantly more common for MTAPdef (n = 48) than for MTAP-proficient (MTAPprof; n = 145) patients (75% vs 55.2%; p = 0.02). MTAPdef was associated with poor prognosis (median overall survival [mOS] 12.3 vs 20.2 mo; p = 0.007) with an adjusted hazard ratio of 1.93 (95% confidence interval 1.35-2.98). Similarly, IMvigor210 patients with MTAPlo (n = 29) had a higher incidence of visceral metastases than those with MTAPhi tumors (n = 269; 86.2% vs 72.5%; p = 0.021) and worse prognosis (mOS 8.0 vs 11.3 mo; p = 0.042). Hyperplasia-associated genes were more frequently mutated in MTAPdef tumors (FGFR3: 31% vs 8%; PI3KCA: 31% vs 19%), while alterations in dysplasia-associated genes were less common in MTAPdef tumors (TP53: 41% vs 67%; RB1: 0% vs 16%). Our findings support a distinct biology in MTAPdef mUC that is associated with early visceral disease and worse prognosis. PATIENT SUMMARY: We investigated the outcomes for patients with the most common gene loss (MTAP gene) in metastatic cancer of the urinary tract. We found that this loss correlates with worse prognosis and a higher risk of metastasis in internal organs. There seems to be distinct tumor biology for urinary tract cancer with MTAP gene loss and this could be a potential target for treatment.
引用
- Alhalabi O, Zhu Y, Hamza A, et al. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol. 2021. PMID: 34789422. doi:10.1016/j.euo.2021.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。